Skip to main content

Antidiuretic Hormone, Inappropriate Secretion

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Otsuka
OtsukaJapan - Tokushima
1 program
TolvaptanN/A1 trial
Active Trials
NCT04790175Active Not Recruiting300Est. Jan 2030

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
OtsukaTolvaptan

Clinical Trials (1)

Total enrollment: 300 patients across 1 trials

Samsca Post-marketing General Drug Use-results Survey in Patients With Hyponatremia in SIADH

Start: Mar 2021Est. completion: Jan 2030300 patients
N/AActive Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.